Fuyuhiko Tamanoi
#153,174
Most Influential Person Now
Researcher
Fuyuhiko Tamanoi's AcademicInfluence.com Rankings
Fuyuhiko Tamanoichemistry Degrees
Chemistry
#4220
World Rank
#5286
Historical Rank
Inorganic Chemistry
#227
World Rank
#241
Historical Rank

Download Badge
Chemistry
Fuyuhiko Tamanoi's Degrees
- PhD Chemistry University of Tokyo
Why Is Fuyuhiko Tamanoi Influential?
(Suggest an Edit or Addition)Fuyuhiko Tamanoi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. (2008) (1539)
- Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. (2010) (917)
- Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. (2007) (911)
- The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae (1990) (637)
- Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. (2010) (530)
- Light-activated nanoimpeller-controlled drug release in cancer cells. (2008) (412)
- Spatial regulation of the exocyst complex by Rho1 GTPase (2001) (339)
- Differential activation of yeast adenylate cyclase by wild type and mutant RAS proteins (1985) (307)
- A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. (2004) (301)
- IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein. (1990) (284)
- Analysis of the transforming potential of the human H-ras gene by random mutagenesis. (1984) (255)
- Identification of Ras farnesyltransferase inhibitors by microbial screening. (1993) (241)
- Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy (2010) (224)
- Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. (2011) (212)
- Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. (2015) (207)
- Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. (2010) (206)
- In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. (2012) (198)
- Rho3 of Saccharomyces cerevisiae, Which Regulates the Actin Cytoskeleton and Exocytosis, Is a GTPase Which Interacts with Myo2 and Exo70 (1999) (198)
- Specific Activation of mTORC1 by Rheb G-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein* (2009) (198)
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer (2010) (196)
- The Rheb family of GTP-binding proteins. (2004) (195)
- Loss of the TOR Kinase Tor2 Mimics Nitrogen Starvation and Activates the Sexual Development Pathway in Fission Yeast (2007) (191)
- Therapeutic intervention based on protein prenylation and associated modifications (2006) (172)
- Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells (2007) (168)
- Neurofibromatosis 2 tumour suppressor schwannomin interacts with βII-spectrin (1998) (164)
- RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer* (2001) (163)
- Drosophila Rheb GTPase is required for cell cycle progression and cell growth (2003) (163)
- Inhibitors of Ras farnesyltransferases. (1993) (159)
- The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. (1995) (149)
- Small-molecule inhibitors of protein geranylgeranyltransferase type I. (2007) (148)
- Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells (2007) (147)
- Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells (2002) (145)
- pH-Operated mechanized porous silicon nanoparticles. (2011) (136)
- Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. (2016) (131)
- The Saccharomyces cerevisiae Rheb G-protein Is Involved in Regulating Canavanine Resistance and Arginine Uptake* (2000) (128)
- Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. (1998) (126)
- Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines (2000) (120)
- Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. (2013) (119)
- Identification of Dominant Negative Mutants of Rheb GTPase and Their Use to Implicate the Involvement of Human Rheb in the Activation of p70S6K* (2003) (118)
- De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. (2013) (112)
- Common modifications of trimeric G proteins and ras protein: involvement of polyisoprenylation. (1990) (112)
- Purification of an adenovirus-coded DNA polymerase that is required for initiation of DNA replication (1982) (112)
- Systematic Identification of Cellular Signals Reactivating Kaposi Sarcoma–Associated Herpesvirus (2007) (111)
- Protein geranylgeranyltransferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product but not the DPR1 gene product. (1991) (109)
- Patterned Hexagonal Arrays of Living Cells in Sol−Gel Silica Films (2000) (107)
- Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene (1996) (105)
- Two-photon-triggered drug delivery via fluorescent nanovalves. (2014) (104)
- IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase-activating protein. (1991) (101)
- Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. (2009) (101)
- Function of adenovirus terminal protein in the initiation of DNA replication. (1982) (100)
- Yeast CAL1 is a structural and functional homologue to the DPR1 (RAM) gene involved in ras processing. (1991) (99)
- Two-photon-triggered drug delivery in cancer cells using nanoimpellers. (2013) (95)
- Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast (2005) (93)
- Differential Requirement of CAAX-mediated Posttranslational Processing for Rheb Localization and Signaling (2009) (91)
- Processing and fatty acid acylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. (1986) (91)
- Mevalonate Pathway and Human Cancers. (2017) (88)
- Mutants of Saccharomyces cerevisiae defective in the farnesylation of Ras proteins. (1990) (88)
- Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin (2010) (86)
- Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells (2001) (81)
- Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control (2008) (80)
- Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases. (1994) (79)
- Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation (2004) (78)
- A novel yeast mutant defective in the processing of ras proteins: assessment of the effect of the mutation on processing steps. (1987) (77)
- Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer (2018) (77)
- Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived Compounds* (2008) (75)
- In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I (2009) (72)
- A product of yeast RAS2 gene is a guanine nucleotide binding protein. (1984) (70)
- Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant (2001) (70)
- Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. (2016) (70)
- Farnesylated proteins and cell cycle progression (2001) (70)
- The Schizosaccharomyces pombe cwg2+ gene codes for the beta subunit of a geranylgeranyltransferase type I required for beta‐glucan synthesis. (1993) (69)
- Activating mutations of TOR (target of rapamycin) (2011) (69)
- Silica nanoparticles as a delivery system for nucleic acid-based reagents. (2009) (68)
- Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. (2018) (67)
- Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. (2017) (67)
- Mutation of a termination codon affects src initiation (1984) (64)
- A novel approach to tag and identify geranylgeranylated proteins (2009) (64)
- Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. (2015) (63)
- Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase (2012) (62)
- The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid. (1991) (62)
- Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress (2006) (61)
- Mechanism of DNA chain growth. XI. Structure of RNA-linked DNA fragments of Escherichia coli. (1973) (61)
- AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. (2008) (60)
- Initiation of adenovirus DNA replication in vitro requires a specific DNA sequence. (1983) (59)
- Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. (2012) (58)
- DNA sequences required for the in vitro replication of adenovirus DNA. (1984) (56)
- Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways (2005) (55)
- Site of linkage between adenovirus type 12 and cell DNAs in hamster tumour line CLAC3 (1981) (55)
- Ras signaling in yeast. (2011) (55)
- Amino Acid Substitutions That Convert the Protein Substrate Specificity of Farnesyltransferase to That of Geranylgeranyltransferase Type I* (1997) (54)
- Recent progress in the study of the Rheb family GTPases. (2014) (53)
- Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer. (2001) (52)
- Structure and expression of yeast DPR1, a gene essential for the processing and intracellular localiation of ras proteins (1988) (50)
- Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. (2015) (48)
- The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast (2008) (47)
- RAS2 protein of Saccharomyces cerevisiae undergoes removal of methionine at N terminus and removal of three amino acids at C terminus. (1990) (46)
- GapIII, a new brain‐enriched member of the GTPase‐activating protein family (1995) (46)
- Purified yeast protein farnesyltransferase is structurally and functionally similar to its mammalian counterpart. (1993) (46)
- Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. (1998) (46)
- The TSC/Rheb/TOR Signaling Pathway in Fission Yeast and Mammalian Cells: Temperature Sensitive and Constitutive Active Mutants of TOR (2007) (45)
- Significance of filamin A in mTORC2 function in glioblastoma (2015) (44)
- IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein (1990) (44)
- Tailoring the biodegradability of porous silicon nanoparticles. (2012) (43)
- Characterization of the Rheb-mTOR signaling pathway in mammalian cells: constitutive active mutants of Rheb and mTOR. (2008) (42)
- Uracil incorporation into nascent DNA of thymine-requiring mutant of Bacillus subtilis 168. (1978) (42)
- Protein Farnesylation Is Critical for Maintaining Normal Cell Morphology and Canavanine Resistance in Schizosaccharomyces pombe * (2000) (42)
- PAK1 Kinase Promotes Cell Motility and Invasiveness through CRK-II Serine Phosphorylation in Non-Small Cell Lung Cancer Cells (2012) (41)
- Nucleotide sequence of the primary origin of bacteriophage T7 DNA replication: relationship to adjacent genes and regulatory elements. (1980) (41)
- A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors* (1999) (40)
- Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. (2014) (40)
- Physical mapping of primary and secondary origins of bacteriophage T7 DNA replication. (1980) (40)
- Replication of bacteriophage T7 DNA by purified proteins. (1979) (39)
- Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. (2016) (38)
- Functional significance of lysine 1423 of neurofibromin and characterization of a second site suppressor which rescues mutations at this residue and suppresses RAS2Val-19-activated phenotypes (1994) (36)
- The Protein Farnesyltransferase Regulates HDAC6 Activity in a Microtubule-dependent Manner* (2009) (34)
- S-farnesylation and methyl esterification of C-terminal domain of yeast RAS2 protein prior to fatty acid acylation. (1991) (34)
- C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. (1996) (33)
- Molecular targets and the treatment of myeloid leukemia. (2006) (33)
- Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles (1996) (33)
- Terminal region recognition factor 1, a DNA-binding protein recognizing the inverted terminal repeats of the pGKl linear DNA plasmids. (1991) (33)
- Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues (2019) (32)
- Initiation of DNA replication at the primary origin of bacteriophage T7 by purified proteins: requirement for T7 RNA polymerase. (1981) (31)
- Posttranslational modification of ras proteins: Detection of a modification prior to fatty acid acylation and cloning of a gene responsible for the modification (1988) (30)
- The origin of adenovirus DNA replication. (1984) (29)
- Characterization of the geranylgeranyl transferase type I from Schizosaccharomyces pombe (1998) (29)
- In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells (2013) (28)
- Kir, a novel Ras-family G-protein, induces invasive pseudohyphal growth in Saccharomyces cerevisiae. (1995) (26)
- Fighting cancer by disrupting C-terminal methylation of signaling proteins. (2004) (25)
- Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis (2015) (25)
- Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy (2019) (24)
- Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter (2014) (24)
- Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape (2021) (24)
- Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. (2012) (24)
- Rheb Protein Binds CAD (Carbamoyl-phosphate Synthetase 2, Aspartate Transcarbamoylase, and Dihydroorotase) Protein in a GTP- and Effector Domain-dependent Manner and Influences Its Cellular Localization and Carbamoyl-phosphate Synthetase (CPSase) Activity* (2014) (24)
- Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase (1997) (24)
- Characterization of Rheb functions using yeast and mammalian systems. (2001) (24)
- Mutant farnesyltransferase beta subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I beta subunit. (1995) (23)
- Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application. (2018) (23)
- Cytosolic and mitochondrial ROS production resulted in apoptosis induction in breast cancer cells treated with Crocin: The role of FOXO3a, PTEN and AKT signaling. (2020) (23)
- Rheb G-Proteins and the Activation of mTORC1. (2010) (23)
- A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. (2017) (23)
- Prenylation of RAS and Inhibitors of Prenyltransferases (1996) (22)
- Anticancer Effect and Molecular Targets of Saffron Carotenoids. (2014) (21)
- Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle‐Based Anticancer Drug (2020) (21)
- Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X-ray Photoelectron Spectroscopy: Cancer Therapy Implications (2019) (20)
- Phosphorylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. (1989) (20)
- Molecular machines involved in protein transport across cellular membranes (2007) (19)
- Energy coupling and molecular motors (2004) (17)
- A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity (1992) (17)
- Characterization of the Raptor/4E-BP1 Interaction by Chemical Cross-linking Coupled with Mass Spectrometry Analysis* (2014) (17)
- A novel metal-chelating inhibitor of protein farnesyltransferase. (2003) (16)
- Identification and Characterization of Mechanism of Action of P61-E7, a Novel Phosphine Catalysis-Based Inhibitor of Geranylgeranyltransferase-I (2011) (16)
- Impact of Pore–Walls Ligand Assembly on the Biodegradation of Mesoporous Organosilica Nanoparticles for Controlled Drug Delivery (2018) (14)
- How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth? (2015) (14)
- Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions. (2013) (13)
- Biochemical characterization of yeast RAS2 mutants reveals a new region of ras protein involved in the interaction with GTPase-activating proteins. (1994) (13)
- The Ras superfamily G-proteins. (2013) (12)
- Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. (2018) (12)
- Adenoviral DNA replication: DNA sequences and enzymes required for initiation in vitro. (1983) (12)
- Relationship between the glutathione-responsive degradability of thiol-organosilica nanoparticles and the chemical structures (2019) (12)
- Drug Release from Three‐Dimensional Cubic Mesoporous Silica Nanoparticles Controlled by Nanoimpellers (2014) (12)
- Persistence of RNA attached to nascent short DNA pieces in Bacillus subtilis cells defective in DNA polymerase I. (1977) (11)
- Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women’s breast cancer tumors (2018) (11)
- Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy (2020) (11)
- Use of yeast two-hybrid system to evaluate Ras interactions with neurofibromin-GTPase-activating protein. (1995) (11)
- Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy (2021) (10)
- New activated RAS2 mutations identified in Saccharomyces cerevisiae. (1993) (10)
- Eukaryotic RNases and their partners in RNA degradation and biogenesis (2012) (9)
- In vitro delivery of calcium ions by nanogated mesoporous silica nanoparticles to induce cancer cellular apoptosis (2017) (9)
- Cloning of the T7 genome in Escherichia coli: use of recombination between cloned sequences and bacteriophage T7 to identify genes involved in recombination and a clone containing the origin of T7 DNA replication. (1979) (9)
- Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. (1995) (9)
- Uracil incorporation into nascent DNA of Bacillus subtilis and Escherichia coli. (1979) (9)
- Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy (2020) (9)
- Structure, function and regulation of TOR complexes from yeasts to mammals (2010) (8)
- On the Mechanism of Adenovirus DNA Replication (1986) (8)
- Conservation of the Tsc/Rheb/TORC1/S6K/S6 Signaling in Fission Yeast. (2010) (8)
- Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction. (2006) (7)
- Natural products and cancer signaling : isoprenoids, polyphenols and flavonoids (2014) (7)
- Chemical Biology / Chemical Genetics / Chemical Genomics : Importance of Chemical Library (2008) (7)
- A two-hybrid approach to identify inhibitors of the RAS-RAF interaction. (2013) (6)
- [5] In vivo assays for farnesyltransferase inhibitors with Saccharomyces cereuisiae (1995) (6)
- Reducing particle size of biodegradable nanomaterial for efficient curcumin loading (2020) (6)
- Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells (2015) (6)
- An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation (2018) (6)
- mTOR Signaling and Human Cancer (2010) (5)
- Phosphatidylinositol 5-phosphate 4-kinase (2012) (5)
- Facile synthesis of biodegradable mesoporous functionalized-organosilica nanoparticles for enhancing the anti-cancer efficiency of cordycepin (2021) (5)
- The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine (2021) (5)
- Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. (2009) (4)
- Mechanism of the anticancer effect of phytochemicals (2015) (4)
- Tuning the Biodegradability of Silicon Nanoparticles for Drug Delivery (2013) (4)
- Initiation ofadenovirus DNA replication invitro requires aspecific DNA sequence (1983) (4)
- Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray (2021) (4)
- Reconstitution of yeast farnesyltransferase from individually purified subunits. (1999) (4)
- Recent excitements in the study of the CAM assay. (2019) (4)
- Inhibitors of the Ras superfamily G-proteins (2013) (4)
- Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy (2012) (4)
- Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. (2017) (4)
- Abstract LB-9: Light-controllable nano-drug delivery system with deep tissue penetrating ability for cancer therapy with two-photon-triggered nanoimpellers (2014) (3)
- Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. (2018) (3)
- Fiber-Optic Based Laser Wakefield Accelerated Electron Beams and Potential Applications in Radiotherapy Cancer Treatments (2022) (3)
- Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth. (2006) (3)
- 3 Mutational analyses of protein farnesyltransferase (2001) (3)
- In vivo assays for farnesyltransferase inhibitors with Saccharomyces cerevisiae. (1995) (3)
- INITIATION OF BACTERIOPHAGE T7 DNA REPLICATION (1981) (2)
- Chapter 7 - Small-Molecule Inhibitors of GGTase-I from the Heterocycle Library Derived from Phosphine Catalysis (2011) (2)
- [Rheb-mTOR signaling pathway involved in tumor formation]. (2010) (2)
- Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models. (2018) (2)
- A genetic approach to the study of farnesylation (1990) (2)
- Inhibitors of the Ras superfamily of small G-proteins. Preface. (2013) (2)
- Phosphorylation of RAS 1 and RAS 2 proteins in Saccharomyces cerevisiae (2)
- Signaling pathways in plants (2014) (2)
- Abstract A09: Therapeutic targeting of TSC2-deficient cells with Methotrexate: Results of a drug repurposing screen (2017) (1)
- Convergence of the Study on Monochromatic X-rays and the Research on Nanoparticles Opens Up a Possibility to Develop a New Type of Radiation Therapy (2020) (1)
- Functional Significance ofLysine 1423ofNeurofibromin and Characterization ofa SecondSiteSuppressor WhichRescues Mutations atThisResidue andSuppresses (1994) (1)
- Engineering Biodegradable Periodic Mesoporous Functionalized-Organosilica Nanocarriers for Efficient Paclitaxel Delivery (2022) (1)
- Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model (2022) (1)
- Genetic Analysis of FTase and GGTase I and Natural Product Farnesyltransferase Inhibitors (2001) (1)
- Analysis of cell–nanoparticle interactions and imaging of in vitro labeled cells showing barcorded endosomes using fluorescent thiol-organosilica nanoparticles surface-functionalized with polyethyleneimine (2022) (1)
- The small molecule compound, MCP1, inhibits Ras-Raf interaction in mammalian cells and induces apoptosis in various hematopoietic cancer cells (2004) (1)
- Characterization of the Raptor / 4 EBP 1 Interaction by Chemical Cross-linking Coupled with Mass Spectrometry Analysis * (2014) (1)
- In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells (2013) (1)
- Coupled with Mass Spectrometry Analysis Interaction by Chemical Cross-linking Characterization of the Raptor/4E-BP1 (2014) (1)
- Effects of farnesyltransferase inhibitors on cell cycle progression of human cancer cells (2001) (1)
- A Novel Metal‐Chelating Inhibitor of Protein Farnesyltransferase. (2003) (1)
- Platelet-activating factor acetylhydrolases (PAF-AH) (2015) (1)
- ID: 4001 Nanoparticle-based Cancer Therapy (2017) (0)
- [Recombinant DNA technology and its use in the study of adenovirus]. (1982) (0)
- Protein farnesyltransferase, alpha subunit (2009) (0)
- Abstract A36: Interruption of K-Ras/PAK1/Crk pathway has a dramatic anti-tumor effect in NSCLC (2014) (0)
- mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin (2022) (0)
- Analysis of the transforming potential of the human Hras gene by random mutagenesis ( oncogenes / in vitro mutagenesis / gene transfer ) (0)
- PTPe (RPTPe and Cyt-PTPe) (2012) (0)
- Welcome to CRRM2017 (2017) (0)
- Abstract LB-243: Discovery of single amino acid changes that confer constitutive activation of mTOR in human cancer (2010) (0)
- Abstract 2702: The mTOR complex 2-associated interactome and cell migration ability determination in brain cancers (2018) (0)
- Magnetic Nanoparticles and Alternating Magnetic Field for Cancer Therapy (2021) (0)
- The enzymes second edition part 2. (2022) (0)
- Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis (2015) (0)
- Development of New Targeted Boronated Small Molecule Drugs for Boron Neutron Capture Therapy (BNCT) (2022) (0)
- Inhibition of DNA synthesis and cancer therapies. (2022) (0)
- An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation (2018) (0)
- Abstract 3906: Characterization of mTORC2 interactome reveals association with microtubules in glioblastoma and neuroblastoma cells (2022) (0)
- Abstract 4535: The mTOR complex 2 promotes glioblastoma migration via the interactions with multiple actin-binding and microtubule-associated proteins (2019) (0)
- Abstract 1670: Characterization of the chick chorioallantoic membrane tumor model in comparison with various xenograft mouse tumors (2020) (0)
- Correction to: Magnetic Nanoparticles and Alternating Magnetic Field for Cancer Therapy (2021) (0)
- 2 Sec Protein-Conducting Channel and SecA (2018) (0)
- Extended characterization of MCP110, an inhibitor of Ras-dependent signaling: Mode of action and preclinical analysis (2004) (0)
- Abstract POSTER-THER-1426: Characterization and targeting of TWIST family proteins to prevent chemoresistance and metastasis in ovarian cancer (2015) (0)
- Organosilica nanoparticles containing sodium borocaptate (BSH) provide new prospects for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy (2023) (0)
- Chips : 98 % Sensitivity and Specificity (2016) (0)
- Significance of filamin A in mTORC2 function in glioblastoma (2015) (0)
- Ras Family G-Proteins in Saccharomyces Cerevisiae and Schizosaccharomyces Pombe (2006) (0)
- The Interaction of Proteins and DNA Sequences Required for Adenovirus DNA Replication in-Vitro (1983) (0)
- TITLE : A Genetic Approach to Define the Importance of Rheb in Tuberous Sclerosis PRINCIPAL INVESTIGATOR : (2006) (0)
- Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer (2018) (0)
- Synthesis of various phosphodiesters and phosphomonoesters with ribonuclease N. (1976) (0)
- “Nanotechnology Cancer Asia-Pacific (NCAP) Network” was launched (2012) (0)
- Studies of Protein Farnesylation in Yeast (2007) (0)
- 10.19 – Smart-Drug Delivery and Target-Specific Therapy (2014) (0)
- 11 - Global Analysis of Prenylated Proteins by the Use of a Tagging via Substrate Approach (2011) (0)
- Abstract 2152: Optimizing therapies for drug-resistant ovarian cancer stem cells using aCAM-PDX model (2018) (0)
- [Function of ras oncogene product]. (1985) (0)
- Abstract P2-07-04: Treatment of metastatic breast cancer using two nanoparticles combined with siRNA targeting Twist1 to inhibit EMT (2015) (0)
- The enzymes first edition. (2022) (0)
- A Genetic Approach to Define the Importance of Rheb in Tuberous Sclerosis (2006) (0)
- Summary of volume 51: DNA damage and double-strand breaks. (2022) (0)
- Controllable drug delivery by light-activated nanoimpellers for cancer therapy (2008) (0)
- Mutant farnesyltransferase subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I (2005) (0)
- Post-Translational Modification of ras Proteins: Palmitoylation and Phosphorylation of Yeast ras Proteins (1989) (0)
- [Recent developments in targeted therapy for cancers and drug discovery]. (2014) (0)
- Overview of DNA damage and double-strand breaks. (2022) (0)
- Targeted and Controlled Release of Anticancer Drugs using Novel Nanoparticles (2015) (0)
- PCAF Lysine Acetyltransferase (2008) (0)
- The enzymes second edition part 1. (2022) (0)
- ID: 1062 The chicken egg tumor model provides an attractive system for evaluating anticancer drugs (2017) (0)
- PC-1 (Human) (2012) (0)
- Auger electrons and DNA double-strand breaks studied by using iodine-containing chemicals. (2022) (0)
- Abstract 219: Identification of the mechanistic target of rapamycin complex 2-associated interactome involved in brain cancer cell motility by affinity purification-mass spectrometry (2017) (0)
- Psk 1 , an AGC kinase family member in fission yeast , is directly phosphorylated and controlled by TORC 1 as S 6 kinase (2012) (0)
- A product of yeast RAS 2 gene is a guanine nucleotide binding protein ( oncogenes / evolution ) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Fuyuhiko Tamanoi?
Fuyuhiko Tamanoi is affiliated with the following schools: